TScan Therapeutics announces updated data from ALLOHA Phase 1 trial

TScan Therapeutics (TCRX) announced updated results from the ongoing ALLOHA Phase 1 trial of TSC-101 in patients with heme malignancies undergoing allogeneic hematopoietic cell transplantation, HCT. The data is being featured in a poster presentation at the 67th American Society of Hematology, ASH, Annual Meeting and Exposition. Key Presentation Highlights: Relapse-free survival and overall survival were improved in the treatment arm relative to the control arm; All 3 TSC-101-treated patients that reached two years of follow-up remained relapse-free as of the data cutoff, compared to 1 of 4 patients in the control arm, consistent with effective elimination of residual cancer cells post-HCT and durable remission with TSC-101 infusion; TSC-101 infusions were well-tolerated at all dose levels, with no dose-limiting toxicities. Observed adverse events were similar across the treatment and control arms and were generally consistent with post-HCT adverse events; Mixed chimerism or relapses following TSC-101 infusions were found to be significantly associated with greater ex vivo expansion of TCR-T cells during the manufacturing process